Group 1A: HR+ Breast Cancer; Novel Targets & Treatments

Wednesday, Dec 14
10:00 am – 11:30 am Eastern Time (US/New York)

Poster #OT1-03-04

Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01

Poster #PD13-09:

Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors

Mentor: Kelly Shanahan, M.D.

In 2008, Kelly Shanahan had everything going for her: a busy and successful ob-gyn practice; a precocious 9-year- old daughter; and a well used passport from traveling all over the world with her family to attend conferences, with a liberal dose of vacation on the side. When she was diagnosed with stage IIB breast cancer in April, she considered it a mere bump in the road.

And for five years, breast cancer was an aside, something to put in the past medical history section of forms. Even when she developed sudden back pain, Kelly never thought it could be breast cancer rearing its ugly head – a pulled muscle, a herniated disc maybe, but not what it turned out to be: metastatic breast cancer in virtually every bone in her body, with a fractured vertebrae and an about to break left femur. Kelly was diagnosed on her 53rd birthday.

Neuropathy from the chemo did cost her her career, but she has found a new purpose in advocacy. Kelly is on the board of METAvivor, a member of the Metastatic Breast Cancer Alliance, a Komen Advocate in Science, a grant reviewer and research advocate. Kelly Shanahan is a mother, a wife, a daughter, a doctor, a woman LIVING with metastatic breast cancer.

Twitter: @stage4Kelly

Scientist: Keerthi Gogineni, M.D.

Keerthi Gogineni, MD, MSHP is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. After completing her undergraduate degree at Brown University, she worked in Washington, DC as a public policy fellow at AIDS Action, a non-profit organization representing AIDS service organizations on Capitol Hill. She went to medical school at the University of Maryland School of Medicine and then completed her residency training in internal medicine and fellowship training in Hematology-Oncology at the Hospital of the University of Pennsylvania in Philadelphia. While there, she completed a Masters of Science in Health Policy Research at the Perelman School of Medicine. Dr. Gogineni was appointed to the Division of Hematology-Oncology at the Hospital of the University of Pennsylvania in 2010 and moved to Atlanta to join the faculty at the Emory School of Medicine in 2015. As a breast oncologist, she guides patients through a complex maze of treatment options and explained potentially debilitating effects of disease and treatment. She takes care of patients at the Glenn Family Breast Center at Winship Cancer Institute and at the Georgia Cancer Center of Excellence at Grady Memorial Hospital and conducts clinical trials in breast cancer and health equity research. Dr. Gogineni also serves as Associate Director of the Hematology and Medical Oncology Fellowship Program and as Co-Vice Chair of Diversity, Equity, and Inclusion in the Department of Hematology and Medical Oncology.